

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. The Phase II SAVANNAH trial is evaluating which of the following combinations for patients with locally advanced or metastatic NSCLC with EGFR mutation, MET amplification or MET overexpression who have experienced disease progression after treatment with osimertinib?**
  - Afatinib/tepotinib
  - Amivantamab/capmatinib
  - Capmatinib/gefitinib
  - Osimertinib/savolitinib**
- 2. In the Phase II VISION study, what was the overall response rate (ORR) with tepotinib in the cohort of patients with NSCLC harboring MET exon 14 skipping mutations?**
  - 16%
  - 26%
  - 46%**
  - 66%
- 3. In the GEOMETRY mono-1 study, what was the ORR with capmatinib in the cohort of patients with treatment-naïve NSCLC harboring MET exon 14 skipping mutations?**
  - 18%
  - 28%
  - 48%
  - 68%**
- 4. What is the most common treatment-related adverse event of any grade associated with tepotinib, capmatinib and savolitinib?**
  - Fatigue
  - Neutropenia
  - Peripheral edema**
  - Peripheral neuropathy
- 5. Which of the following drug types best describes the mechanism of action of amivantamab?**
  - MET-directed monoclonal antibody
  - EGFR tyrosine kinase inhibitor
  - MET x CD3 bispecific antibody
  - MET x EGFR bispecific antibody**